Sugi Predict

Sugi Predict / Compounds / SCHEMBL1135006

SCHEMBL1135006

SCHEMBL1135006

O=Cc1cnc2[nH]ccc2c1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKCI P41743 3/20 0.59
▸ AXL P30530 2/20 0.59
▸ KMT2A Q03164 1/20 0.41
▸ TTBK1 Q5TCY1 3/20 0.37
▸ TTBK2 Q6IQ55 3/20 0.37
▸ CDK8 P49336 2/20 0.37
▸ NUDT1 P36639 4/20 0.36
▸ CCNK O75909 1/20 0.36
▸ CDK12 Q9NYV4 1/20 0.36
▸ JAK2 O60674 4/20 0.35
▸ JAK1 P23458 2/20 0.35
▸ TYK2 P29597 1/20 0.35
▸ FGFR1 P11362 3/20 0.35
▸ KDR P35968 2/20 0.35
▸ FGFR2 P21802 1/20 0.35
▸ FGFR3 P22607 1/20 0.35
▸ JAK3 P52333 3/20 0.34
▸ AURKB Q96GD4 2/20 0.34
▸ RET P07949 2/20 0.34
▸ LTK P29376 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29817501 1.00 PRKCI (0.59) PRKCIAXLKMT2ATTBK1TTBK2
SCHEMBL21121074 0.78 PRKCI (0.42) PRKCIAXLKMT2ATTBK1TTBK2
SCHEMBL28835909 0.78 PRKCI (0.54) PRKCIAXLTTBK1TTBK2CDK8
SCHEMBL1366783 0.78 AXL (0.50) PRKCIAXLTTBK1TTBK2CDK8
SCHEMBL1366781 0.78 AXL (0.50) PRKCIAXLTTBK1TTBK2CDK8
SCHEMBL1952520 0.77 PRKCI (0.49) PRKCIAXLKMT2ATTBK1TTBK2
SCHEMBL1356886 0.77 PRKCI (0.67) PRKCIAXLTTBK1TTBK2CDK8
SCHEMBL1134969 0.76 PRKCI (0.44) PRKCIAXLKMT2ACDK8NUDT1
SCHEMBL19012163 0.76 PRKCI (0.55) PRKCIAXLTTBK1TTBK2NUDT1
SCHEMBL25240202 0.75 PRKCI (0.39) PRKCIAXLKMT2ACDK8NUDT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112867716-A Solid forms of FGFR inhibitors and methods for their preparation 因赛特公司 2021-05-28 — — CN claimed
EP-3737680-A1 OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS F. Hoffmann-La Roche AG (CH) 2020-11-18 — — EP claimed
US-20190337948-A1 SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME WILMINGTON PHARMATECH 2019-11-07 — — US claimed
WO-2019134985-A1 OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2019-07-11 — — WO claimed
US-12552792-B2 Solid forms of an FGFR inhibitor and processes for preparing the same INCYTE CORPORATION (US) 2026-02-17 — — US disclosed
US-12534463-B2 Substituted tricyclic compounds as FGFR inhibitors INCYTE CORPORATION (US) 2026-01-27 — — US disclosed
US-20250276970-A1 DERIVATIVES OF AN FGFR INHIBITOR INCYTE CORPORATION 2025-09-04 — — US disclosed
US-12168660-B2 Derivatives of an FGFR inhibitor INCYTE CORPORATION (US) 2024-12-17 — — US disclosed
US-20240300948-A1 Heterocyclic Compounds As Kinase Inhibitors INCYTE CORPORATION 2024-09-12 — — US disclosed
EP-3788047-B1 SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME INCYTE CORP (US) 2024-09-04 — — EP disclosed
US-20240246974-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS INCYTE CORPORATION 2024-07-25 — — US disclosed
EP-4403216-A2 SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS Incyte Holdings Corporation (US) 2024-07-24 — — EP disclosed
US-20090312338-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2009-12-17 — — US disclosed
US-20090312338-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2009-12-17 — — US disclosed
US-20090312338-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2009-12-17 — — US disclosed
US-7589101-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2009-09-15 — — US disclosed
CN-101437822-A Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2009-05-20 — — CN disclosed
US-20080287432-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-11-20 — — US disclosed
CN-101291938-A Compounds and compositions as protein kinase inhibitors IRM LLC THE SCRIPPS RES INST (BM) 2008-10-22 — — CN disclosed
WO-2007134259-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-11-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190337948-A1 SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME FGFR1, FGFR2, FGFR3 PRKCI 718/4885AXL 15/4885KMT2A 745/4885
US-12168660-B2 Derivatives of an FGFR inhibitor FGFR1, FGFR2, FGFR4 PRKCI 2907/4885AXL 77/4885KMT2A 892/4885
US-12534463-B2 Substituted tricyclic compounds as FGFR inhibitors FGFR3, FGFR1, FGFR4 PRKCI 3575/4885AXL 91/4885KMT2A 1681/4885
US-20250276970-A1 DERIVATIVES OF AN FGFR INHIBITOR FGFR1, FGFR2, FGFR4 PRKCI 2907/4885AXL 77/4885KMT2A 892/4885
US-20240246974-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS FGFR3, FGFR1, FGFR2 PRKCI 1091/4885AXL 131/4885KMT2A 720/4885
US-20080287432-A1 Compounds and Compositions as Protein Kinase Inhibitors AURKC, PTK2B, FRK PRKCI 271/4885AXL 240/4885KMT2A 1068/4885
US-20090312338-A1 Novel Tricyclic Compounds CYP11B2, CYP11B1, ABCB1 PRKCI 3201/4885AXL 3812/4885KMT2A 3801/4885
US-12552792-B2 Solid forms of an FGFR inhibitor and processes for preparing the same FGFR2, FGFR1, FGF2 PRKCI 1589/4885AXL 101/4885KMT2A 2450/4885
US-20240300948-A1 Heterocyclic Compounds As Kinase Inhibitors JAK2, JAK1, JAK3 PRKCI 188/4885AXL 422/4885KMT2A 631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.